Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 2
1961 2
1962 2
1964 2
1965 2
1966 6
1967 5
1968 6
1969 3
1970 10
1971 2
1972 10
1973 2
1974 4
1975 9
1976 11
1977 15
1978 17
1979 15
1980 17
1981 17
1982 22
1983 29
1984 33
1985 53
1986 49
1987 67
1988 60
1989 65
1990 59
1991 63
1992 60
1993 65
1994 55
1995 73
1996 76
1997 72
1998 87
1999 104
2000 94
2001 93
2002 102
2003 131
2004 115
2005 155
2006 158
2007 165
2008 179
2009 183
2010 219
2011 263
2012 270
2013 329
2014 320
2015 301
2016 286
2017 278
2018 241
2019 263
2020 305
2021 356
2022 362
2023 316
2024 75

Text availability

Article attribute

Article type

Publication date

Search Results

6,118 results

Results by year

Filters applied: . Clear all
Page 1
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01.
Shimizu T, Sands J, Yoh K, Spira A, Garon EB, Kitazono S, Johnson ML, Meric-Bernstam F, Tolcher AW, Yamamoto N, Greenberg J, Kawasaki Y, Zebger-Gong H, Kobayashi F, Phillips P, Lisberg AE, Heist RS. Shimizu T, et al. Among authors: yamamoto n. J Clin Oncol. 2023 Oct 10;41(29):4678-4687. doi: 10.1200/JCO.23.00059. Epub 2023 Jun 16. J Clin Oncol. 2023. PMID: 37327461 Free PMC article. Clinical Trial.
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer.
Hotta K, Hida T, Nokihara H, Morise M, Kim YH, Azuma K, Seto T, Takiguchi Y, Nishio M, Yoshioka H, Kumagai T, Watanabe S, Goto K, Satouchi M, Kozuki T, Shukuya T, Nakagawa K, Mitsudomi T, Yamamoto N, Asakawa T, Yoshimoto T, Takata S, Tamura T. Hotta K, et al. Among authors: yamamoto n. ESMO Open. 2022 Aug;7(4):100527. doi: 10.1016/j.esmoop.2022.100527. Epub 2022 Jul 14. ESMO Open. 2022. PMID: 35843080 Free PMC article. Clinical Trial.
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome.
Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, Mishima H, Hattori H, Funakoshi T, Kojima T, Sasada T, Sato E, Okamoto S, Tomura D, Nukaya I, Chono H, Mineno J, Kairi MF, Diem Hoang Nguyen P, Simoni Y, Nardin A, Newell E, Fehlings M, Ikeda H, Watanabe T, Shiku H. Ishihara M, et al. Among authors: yamamoto n. J Immunother Cancer. 2022 Jun;10(6):e003811. doi: 10.1136/jitc-2021-003811. J Immunother Cancer. 2022. PMID: 35768164 Free PMC article. Clinical Trial.
Sore thumb syndrome.
Yamamoto N. Yamamoto N. Clin Exp Nephrol. 2023 Aug;27(8):715-716. doi: 10.1007/s10157-023-02354-w. Epub 2023 Apr 24. Clin Exp Nephrol. 2023. PMID: 37095346 No abstract available.
Randomized Phase 2 Study of Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations: WJOG9717L Study.
Kenmotsu H, Wakuda K, Mori K, Kato T, Sugawara S, Kirita K, Yoneshima Y, Azuma K, Nishino K, Teraoka S, Shukuya T, Masuda K, Hayashi H, Toyozawa R, Miura S, Fujimoto D, Nakagawa K, Yamamoto N, Takahashi T. Kenmotsu H, et al. Among authors: yamamoto n. J Thorac Oncol. 2022 Sep;17(9):1098-1108. doi: 10.1016/j.jtho.2022.05.006. Epub 2022 May 27. J Thorac Oncol. 2022. PMID: 35636696 Free article. Clinical Trial.
NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
de Castro G Jr, Rizvi NA, Schmid P, Syrigos K, Martin C, Yamamoto N, Cheng Y, Moiseyenko V, Summers Y, Vynnychenko I, Lee SY, Bryl M, Zer A, Erman M, Timcheva C, Raja R, Naicker K, Scheuring U, Walker J, Mann H, Chand V, Mok T; NEPTUNE Investigators. de Castro G Jr, et al. Among authors: yamamoto n. J Thorac Oncol. 2023 Jan;18(1):106-119. doi: 10.1016/j.jtho.2022.09.223. Epub 2022 Oct 12. J Thorac Oncol. 2023. PMID: 36240972 Free article. Clinical Trial.
Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (CAPITAL): a randomised, multicentre, open-label, phase 3 trial.
Kogure Y, Iwasawa S, Saka H, Hamamoto Y, Kada A, Hashimoto H, Atagi S, Takiguchi Y, Ebi N, Inoue A, Kurata T, Okamoto I, Yamaguchi M, Harada T, Seike M, Ando M, Saito AM, Kubota K, Takenoyama M, Seto T, Yamamoto N, Gemma A. Kogure Y, et al. Among authors: yamamoto n. Lancet Healthy Longev. 2021 Dec;2(12):e791-e800. doi: 10.1016/S2666-7568(21)00255-5. Lancet Healthy Longev. 2021. PMID: 36098037 Free article. Clinical Trial.
Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility.
Fujimoto D, Morimoto T, Tamiya M, Hata A, Matsumoto H, Nakamura A, Yokoyama T, Taniguchi Y, Uchida J, Sato Y, Yokoi T, Tanaka H, Furuya N, Masuda T, Sakata Y, Miyauchi E, Hara S, Saito G, Miura S, Kanazu M, Yamamoto N, Akamatsu H. Fujimoto D, et al. Among authors: yamamoto n. JAMA Netw Open. 2023 Feb 1;6(2):e230698. doi: 10.1001/jamanetworkopen.2023.0698. JAMA Netw Open. 2023. PMID: 36826813 Free PMC article.
Transcriptomic Analyses of Pretreatment Tumor Biopsy Samples, Response to Neoadjuvant Chemoradiotherapy, and Survival in Patients With Advanced Rectal Cancer.
Akiyoshi T, Wang Z, Kaneyasu T, Gotoh O, Tanaka N, Amino S, Yamamoto N, Kawachi H, Mukai T, Hiyoshi Y, Nagasaki T, Yamaguchi T, Konishi T, Fukunaga Y, Noda T, Mori S. Akiyoshi T, et al. Among authors: yamamoto n. JAMA Netw Open. 2023 Jan 3;6(1):e2252140. doi: 10.1001/jamanetworkopen.2022.52140. JAMA Netw Open. 2023. PMID: 36662520 Free PMC article.
6,118 results